Spontaneous abortion during ustekinumab therapy

Journal of Dermatological Case Reports

Volumn 6, Issue 4, 2012, Pages 105-107

  Fotiadou, Christina ^a   Lazaridou, Elizabeth ^a   Sotiriou, Eleni ^a   Ioannides, Demetrios ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Abortion; Biologic agents; Pregnancy outcomes; Psoriasis; Ustekinumab

Indexed keywords

USTEKINUMAB;

ABORTION; ADULT; ARTICLE; CASE REPORT; FEMALE; HUMAN; PREGNANCY OUTCOME; PSORIASIS; RISK FACTOR;

EID: 84930472965     PISSN: None     EISSN: 18987249     Source Type: Journal    
DOI: 10.3315/jdcr.2012.1116     Document Type: Article

References (15)

1. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, et al. Efficacy and safe-ty of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHO-ENIX 1). Lancet. 2008; 371: 1665-1674.
2. European Medicines Agency. Stelara, European Public Asses-sment Report. EPARs for authorised medicinal products for human use. 2009. Available at: http://www.emea.euro-pa.eu/humandocs/Humans/EPAR/stelara/stelara.htm.
3. Data on File. Reports of pregnancy with ustekinumab: STE/Inj/DoF/Sep2010 /EMEA001. 2010, Janssen.
4. Simister NE. Placental transport of immunoglobulin G. Vacci-ne. 2003; 21: 3365-3369.
5. Martin PL, Sachs C, Imai N, Tsusaki H, Oneda S, Jiao Q, Tre-acy G. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-il12/23 p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010; 89: 351-363.
6. Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL. Anti-TNF therapies and pregnancy: outcome of 130 pregnan-cies in the British Society for Rheumatology Biologics Regi-ster. Ann Rheum Dis. 2011; 70: 823-826.
7. Kwak-Kim JY, Gilman-Sachs A, Kim CE. T helper 1 and 2 im-mune responses in relationship to pregnancy, nonpregnan-cy, recurrent spontaneous abortions and infertility of repe-ated implantation failures. Chem Immunol Allergy. 2005; 88: 64-79.
8. Ben-David G, Sheiner E, Hallak M, Levy A. Pregnancy out-come in women with psoriasis. J Reprod Med. 2008; 53: 183-187.
9. Yang YW, Chen CS, Chen YH, Lin HC. Psoriasis and pregnan-cy outcomes: a nationwide population-based study. J Am Acad Dermatol. 2011; 64: 71-77.
10. Guven MA, Coskun A, Ertas IE, Aral M, Zencirci B, Oksuz H. Association of maternal serum CRP, IL-6, TNF-alpha, homo-cysteine, folic acid and vitamin B12 levels with the severity of preeclampsia and fetal birth weight. Hypertens Pregnancy. 2009; 28: 190-200.
11. Bandoli G, Johnson DL, Jones KL, Lopez Jiminez J, Salas E, Mirrasoul N, Van Voorhees AS, Chambers CD. Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. Br J Dermatol. 2010; 163: 334-339.
12. Cohen-Barak E, Nachum Z, Rozenman D, Ziv M. Pregnancy outcomes in women with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2011; 25: 1041-1047.
13. Seeger JD, Lanza LL, West WA, Fernandez C, Rivero E. Pre-gnancy and pregnancy outcome among women with inflam-matory skin diseases. Dermatology. 2007; 214: 32-39.
14. Wilcox AJ, Weinberg CR, O'Connor JF, Baird DD, Schlatterer JP, Canfield RE, Armstrong EG, Nisula BC. Incidence of early loss of pregnancy. N Engl J Med. 1988; 319: 189-194.
15. Kramer MS. The epidemiology of adverse pregnancy outco-mes: an overview. J Nutr. 2003; 133(5 Suppl 2): 1592S-1596S.